GMTX vs. LGND, IRWD, GYRE, PRTA, BLTE, SYRE, PCRX, MIRM, COLL, and MNKD
Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Gyre Therapeutics (GYRE), Prothena (PRTA), Belite Bio (BLTE), Spyre Therapeutics (SYRE), Pacira BioSciences (PCRX), Mirum Pharmaceuticals (MIRM), Collegium Pharmaceutical (COLL), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Gemini Therapeutics (NASDAQ:GMTX) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, media sentiment, institutional ownership, earnings, profitability, valuation and risk.
Ligand Pharmaceuticals received 512 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 69.96% of users gave Ligand Pharmaceuticals an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500.
Ligand Pharmaceuticals has a net margin of 79.30% compared to Gemini Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 8.52% beat Gemini Therapeutics' return on equity.
Ligand Pharmaceuticals has a consensus target price of $116.33, indicating a potential upside of 33.29%. Given Ligand Pharmaceuticals' higher possible upside, analysts clearly believe Ligand Pharmaceuticals is more favorable than Gemini Therapeutics.
Ligand Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 10.4% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Ligand Pharmaceuticals had 22 more articles in the media than Gemini Therapeutics. MarketBeat recorded 22 mentions for Ligand Pharmaceuticals and 0 mentions for Gemini Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.72 beat Gemini Therapeutics' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.
Summary
Ligand Pharmaceuticals beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.
Get Gemini Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemini Therapeutics Competitors List
Related Companies and Tools
